Clinical Trials Directory

Trials / Terminated

TerminatedNCT06078501

MisOpRostol Effect on Second Trimester Abortion Blood Loss

Misoprostol Effect on Second Trimester Abortion Blood Loss

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
7 (actual)
Sponsor
Stanford University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Although serious complications from second trimester abortion are rare hemorrhage is the most common cause of procedural abortion related morbidity and mortality. Misoprostol is a prostaglandin E1 analogue that is used by 75% of clinicians prior to procedural abortion for the purpose of cervical preparation. Misoprostol is also known to decrease blood loss in first trimester abortion and is used to treat postpartum hemorrhage, however the effect of preprocedural misoprostol on procedural blood loss is not well described. We will conduct a double blinded placebo-controlled gestational age stratified superiority trial of those undergoing procedural abortion between 18 and 23 weeks gestation at Stanford Health care. Participants will be randomized to either 400mcg buccal misoprostol or placebo on the day of the procedure. A quantified blood loss (QBL) will be measured during the procedure and participants will complete a survey to assess symptoms. Our primary outcome is quantified blood loss. Secondary outcomes include clinical interventions to manage excess bleeding, total procedure time, provider reported experience, patient reported experience.

Conditions

Interventions

TypeNameDescription
DRUGMisoprostol 400mcg buccalMisoprostol 400mcg buccal administration 2-3 hours prior to procedure
DRUGPlaceboPlacebo buccal administration 2-3 hours prior to procedure

Timeline

Start date
2024-02-08
Primary completion
2024-07-12
Completion
2024-07-12
First posted
2023-10-12
Last updated
2025-08-24
Results posted
2025-08-24

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT06078501. Inclusion in this directory is not an endorsement.